Enzo Veltri

Learn More
BACKGROUND Eribulin was recently approved in patients progressing after being treated with anthracyclines and taxanes and after two or more chemotherapy lines for advanced disease. OBJECTIVES This multicenter observational retrospective study was performed in order to evaluate activity and tolerability of eribulin in real-world patient population. (More)
BACKGROUND Bevacizumab plus chemotherapy prolongs progression-free survival (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC). Although there is strong evidence to suggest that the mutational status of the K-ras oncogene has a role as a predictive factor for activity in patients treated with cetuximab and panitumumab, few data have been(More)
We discuss deployment solutions for e-Government Interoperability Frameworks (GIFs). We concentrate on middleware-oriented GIFs, i.e., those in which middleware modules act as intermediaries among information systems that need to exchange data and services. A prominent example is the Italian SPCoop interoperability framework. We review the SPCoop(More)
  • Annamaria Ruzzo, Francesco Graziano, Fabio Galli, Elisa Giacomini, Irene Floriani, Francesca Galli +24 others
  • 2014
We investigated 17 polymorphisms in 11 genes (TS, MTHFR, ERCC1, XRCC1, XRCC3, XPD, GSTT1, GSTP1, GSTM1, ABCC1, ABCC2) for their association with the toxicity of fluoropyrimidines and oxaliplatin in colorectal cancer patients enrolled in a prospective randomized trial of adjuvant chemotherapy. The TOSCA Italian adjuvant trial was conducted in high-risk stage(More)
  • 1